The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine.

MLA

Katzendobler, Sophie, et al. “The Value of Stereotactic Biopsy of Primary and Recurrent Brain Metastases in the Era of Precision Medicine.” Frontiers in Oncology, vol. 12, Dec. 2022, p. 1014711. EBSCOhost, https://doi.org/10.3389/fonc.2022.1014711.

APA

Katzendobler, S., Do, A., Weller, J., Rejeski, K., Dorostkar, M. M., Albert, N. L., Forbrig, R., Niyazi, M., Egensperger, R., Tonn, J.-C., von Baumgarten, L., Quach, S., & Thon, N. (2022). The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine. Frontiers in Oncology, 12, 1014711. https://doi.org/10.3389/fonc.2022.1014711

Chicago

Katzendobler, Sophie, Anna Do, Jonathan Weller, Kai Rejeski, Mario M Dorostkar, Nathalie L Albert, Robert Forbrig, et al. 2022. “The Value of Stereotactic Biopsy of Primary and Recurrent Brain Metastases in the Era of Precision Medicine.” Frontiers in Oncology 12 (December): 1014711. doi:10.3389/fonc.2022.1014711.